NUE vs EMR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 19, 2026

NUE

49.4
AI Score
VS
EMR Wins

EMR

50.1
AI Score

Investment Advisor Scores

NUE

49score
Recommendation
HOLD

EMR

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric NUE EMR Winner
Revenue 19.89B 13.78B NUE
Net Income 1.90B 1.94B EMR
Net Margin 9.5% 14.1% EMR
ROE 8.6% 9.5% EMR
ROA 5.1% 4.6% NUE
Total Assets 36.95B 42.21B EMR
Current Ratio 2.51 0.90 NUE
Free Cash Flow 1.05B 2.62B EMR

Relative Price Performance (Last 90 Days)

NUE 1M: +4.0% · 3M: +3.8% EMR 1M: +3.0% · 3M: +7.7%

Current Technical Phase

NUE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 54

RSI (14): 54.2 · Price: $256.98

EMR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.6% over 20 days), RSI 51

RSI (14): 51.3 · Price: $159.29

Fundamentals Snapshot

Metric NUE EMR
Market Cap — —
Forward P/E 12.6 22.4
Trailing P/E 20.9 35.1
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.2% 0.5%
Operating Margin 0.2% 0.3%
EPS 12.54 4.57
Dividend Yield 0.01% 0.01%

Frequently Asked Questions

Based on our detailed analysis, EMR is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.